1304-85-4O=[N+]([O-])[O-].O=[N+]([O-])[O-].O=[N+]([O-])[O-].O=[N+]([O-])[O-].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[O-2].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-]QGWDKKHSDXWPET-UHFFFAOYSA-EBismuth subnitrate, also referred to as bismuth oxynitrate or bismuthyl nitrate, is a highly water-soluble crystalline compound that has been used as a treatment for duodenal ulcers and anti-diarrheic agent. The use of bismuth substrate as an active ingredient in over-the-counter antacids is approved by the FDA.
1304-85-4、54392-33-5DTXSID40893872CHEMBL3833348HEAVY, MICROCRYSTALLINE POWDER
WHITE POWDER
Insoluble
PRACTICALLY INSOL IN WATER, ALC; SOL IN DILUTE HYDROCHLORIC ACID & NITRIC ACID
PRACTICALLY INSOL IN ORGANIC SOLVENTS
Decomposes at 260
BOILING POINT: 260 °C -HNO3 /BIONO3.H2O/
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
This chemical does not meet GHS hazard criteria for 58.1% (115 of 198) of all reports.
Danger
H272 (24.2%): May intensify fire; oxidizer [Danger Oxidizing liquids; Oxidizing solids]
P210, P220, P260, P261, P264, P264+P265, P270, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P370+P378, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 198 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Danger
Chemical: Bismuth hydroxide nitrate oxide, (Bi5(OH)9(NO3)4O)
Bismuth hydroxide nitrate oxide (Bi5(OH)9(NO3)4O) is listed on the EPA's Chemical Data Reporting (CDR) system. Manufacturers and importers of Bismuth hydroxide nitrate oxide (Bi5(OH)9(NO3)4O) are required to report information about their production and use of this chemical to the EPA under the Toxic Substances Control Act (TSCA). (40 eCFR Part 711)
REACH registered substance: Bismuth hydroxide nitrate oxide (EC: 215-136-8)
Bismuth hydroxide nitrate oxide: HSNO Approval: HSR001433 Approved with controls
Ox. Sol. 2 (24.2%)
Specific target organ toxicity - Single exposure - Category 2 (central nervous system, blood)
A - Alimentary tract and metabolism
QA - Alimentary tract and metabolism
Bismuth subnitrate acts as an antacid that exert protective effects on the gastric mucosa. In a double-blind endoscopically controlled study, bismuth substrate was demonstrated to be effective for symptomatic relief in duodenal ulcers. In the alcohol model of mucosal injury in the rat, bismuth substrate was shown to be cytoprotective. In a randomized clinical study consisting of patients with _H. pylori_-associated duodenal ulcer, adjunctive use of colloidal bismuth subnitrate in a short treatment regimen with omeprazole and clarithromycin resulted in improved eradication rate of _H. pylori_.
Based on the findings of a clinical investigation in patients with duodenal ulcer disease and healthy volunteers receiving oral bismuth subnitrate tablets, the protective effects of bismuth subnitrate may be secondary to endogenous mucosal prostaglandin (PGE2) production, which is one of the deficient factors observed in peptic ulcer disease. Antacid neutralizing activity of bismuth subnitrate was demonstrated to have a significant postprandial effect on gastric pH.
BISMUTHUM SUBNITRICUM
Bismuth [CS]; Bismuth [EPC]
BISMUTH SUBNITRATE
Bismuth [CS]; Bismuth [EPC]
Decomposes at 260
260 °C DECOMP
...MATERIALS WHICH ARE TOXIC AS STORED OR WHICH CAN DECOMPOSE INTO TOXIC COMPONENTS...SHOULD BE STORED IN A COOL, WELL-VENTILATED PLACE, OUT OF THE DIRECT RAYS OF THE SUN, AWAY FROM...FIRE HAZARD...PERIODICALLY INSPECTED & MONITORED. /NITRATES/
Keep well closed and protect from light.
ESPECIALLY IN INFANTS, THE SUBNITRATE MAY BE REDUCED BY BACTERIA WITHIN THE BOWEL, TO YIELD NITRITE, WHICH CAUSES METHEMOGLOBINEMIA AFTER ABSORPTION.
A PT POISONED BY TAKING 8 G OF BISMUTH SUBNITRATE TEMPORARILY HAD FOGGY VISION ON 2ND DAY OF POISONING.
CLIN SYMPTOMS AND LAB EXAM FINDINGS OF CASE OF POISONING (CENTRAL NERVOUS SYSTEM SYNDROME) AFTER A LONG-TERM INTAKE OF BI SUBNITRICUM (3 G/DAY, 2-3 WK) ARE REPORTED. DISCONTINUATION OF DRUG COMPLETELY IMPROVED CLIN SYMPTOMS.
ORAL ADMIN...PRODUCES POISONING THROUGH THE FORMATION OF NITRITES.
FOLLOWING SC INJECTIONS (5 G OF BISMUTH SUBNITRATE EACH DAY FOR 3 DAYS), DEGENERATIVE CHANGES & INTRANUCLEAR & INTRACYTOPLASMIC INCLUSIONS APPEARED IN RENAL PROXIMAL TUBULES OF RABBITS.
.../TREATMENT/ OF DOGS BY DAILY SC INJECTION OF BISMUTH SUBNITRATE...INDUCED IRRITATION OF EYES & LACRIMATION & RESULTED IN DEVELOPMENT OF WHITE OPACITIES IN UPPER 2/3 OF CORNEAS.
MICRONIZED HEAVY BISMUTH SUBNITRATE FED TO 99 FEMALE SPF RATS 60-70 DAYS (BI 5 G/KG/DAY), WITH 69 RATS AS CONTROLS. TEST ANIMALS BODY WT MUCH LOWER. DIFFERENCES IN LIVER & KIDNEY WT OF 2 GROUPS. TEST ANIMALS BI BLOOD & CEREBRAL LEVELS 200 & 5 TIMES HIGHER, RESPECTIVELY.
IN MICE, BI SUBNITRATE (0.4 ML/20 G OF STD SOLN, IV) WAS LETHAL WHEN DISSOLVED IN WATER, BUT NOT WHEN IN NACL SOLN. MICE ADMIN 500 MG/KG ORALLY HAD SOFTER STOOLS, AS COMPARED TO CONTROLS, AND FACIAL EDEMA.
For more Non-Human Toxicity Excerpts (Complete) data for BISMUTH SUBNITRATE (6 total), please visit the HSDB record page.
Bismuth subnitrate may undergo minimal gastrointestinal absorption which may be potentiated with concomitant administration of sulfhydryl compounds when dissolved in citrate buffer solution. Approximately 0.2% of orally administered bismuth is absorbed systematically from the gastrointestinal tract with the peak plasma concentration typically occurring within 1 hour.
Bismuth may undergo both urinary and faecal excretion, however the exact proportion contributed by each route is still unknown.
Bismuth has been shown to accumulate preferentially in the kidneys.
No pharmacokinetic data available.
WITH DAILY ORAL ADMIN OF 0.5 G/KG BISMUTH SUBNITRATE, BLOOD BI LEVELS WERE GREATER WITH HEAVY MICRONIZED (665 UG/L) THAN WITH ORDINARY HEAVY BI SUBNITRATE (85 UG/L). KIDNEY BI LEVELS WERE 17 TIMES GREATER THAN LIVER LEVELS WHILE LITTLE BI PASSED INTO THE BRAIN.
Used to make enamel fluxes, cosmetics, antacids, and antiulceratives; [Merck Index] Used as an astringent, adsorbent, and protective; in topical lotions and ointments; [HSDB]
Enameling [Category: Hobbies]
IN PREPN OF MILK OF BISMUTH, AS ASTRINGENT, ADSORBENT, & PROTECTANT
COATING AGENT IN PREPARATIONS FOR GASTRITIS; IN BLEACHING CREAMS
Medication
GRADES: TECHNICAL; CP; NF.
VET: /9% BISMUTH SUBNITRATE FORMULATION/... FOR TREATMENT OF SKIN CONDITIONS SUCH AS MINOR WOUNDS, ABRASIONS, ECZEMAS & INFLAMMATION OF EXTERNAL EAR CANAL.
Paint and Coating Manufacturing
Bismuth hydroxide nitrate oxide (Bi5(OH)9(NO3)4O): ACTIVE
INCOMPATIBILITIES: ALKALINE BICARBONATES, SOLUBLE IODIDES, GALLIC ACID, CALOMEL, SALICYLIC ACID, TANNIN, SULFUR.
(VET): HAS BEEN USED EXTERNALLY IN DUSTING POWDERS FOR INDOLENT, MOIST OR SUPPURATING LESIONS, & AS AN X-RAY CONTRAST MEDIUM.
DescriptionBismuth subnitrate, also referred to as bismuth oxynitrate or bismuthyl nitrate, is a highly water-soluble crystalline compound that has been used as a treatment for duodenal ulcers and anti-diarrheic agent. The use of bismuth substrate as an active ingredient in over-the-counter antacids is approved by the FDA. Bismuth Subnitrate is a basic salt that contains the equivalent of not less than 79.0 percent of bismuth trioxide (Bi2O3),calculated on the dried basis.It is both odorless and tasteless, and is used in bleaching and freckle creams, and hair dyes. Bismuth subnitrate has been used to induce metallothionein in heart tissue and kidneys and to attenuate the toxicity of Adriamycin and cisplatin compounds, respectively.
Usesmanufacture of bismuth fluxes for enamels; in cosmetics.
UsesBismuth subnitrate (BiNO3) is used in the cosmetics industry and to make ceramic and enamel glazes.
UsesIt is used pharmaceutically in wound dressing, ointment component and as an antiacid. In cosmetics it is used as a cosmetic white pigment. Used in Ceramic glazes and enamel fluxes.